Sanofi receives Investment Bank Analyst Rating Update
PARIS (Reuters) -French drugmaker Sanofi (NASDAQ:SNY) said it expected a positive boost to its third-quarter business results from movements on the currency markets, helped by...
By Natalie Grover, Amna Karimi and Pushkala Aripaka (Reuters) -Britain's GSK has appointed its first female chief financial officer, Julie Brown, to succeed Iain Mackay, as the...
Recently spun off from global health giant GlaxoSmithKline (NYSE:GSK), Haleon (NYSE:HLN) is a powerhouse. The provider of over-the-counter medicines and treatments has sales in...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
|Average||70.75 (+86.09% Upside)|
|No. of Analysts||2|